Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

American Journal of Medicine

Volumn 115, Issue 7, 2003, Pages 554-559

  Wang, Rex T ^a   Koretz, Ronald L ^b   Yee Jr , Hal F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; FENFLURAMINE; FLUVOXAMINE; STATIN;

AMINOTRANSFERASE BLOOD LEVEL; AUTOMATION; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DIET; EXERCISE; FATTY LIVER; GASTROPLASTY; HUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 0242361302     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00449-2     Document Type: Review

References (28)

1. Ludwig J., McGill D.B., Lindor K.D. Review non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 12:1997;398-403.
2. Sheth S., Gordon F., Chopra S. Non-alcoholic steatohepatitis. Ann Intern Med. 126:1997;137-145.
3. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease a spectrum of clinical and pathological severity. Gastroenterology. 116:1999;1413-1419.
4. Lee R.G. Non-alcoholic steatohepatitis a study of 49 patients. Hum Pathol. 20:1989;594-598.
5. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of non-alcoholic steatohepatitis a follow up study of forty-two patients for up to 21 years. Hepatology. 11:1990;74-80.
6. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwanedr-Tetri B.A. Non-alcoholic steatohepatitis an expanded clinical entity. Gastroenterology. 107:1994;1103-1109.
7. Caldwell S.H., Oelsner D.H., Lezzoni J.C., et al. Cryptogenic cirrhosis clinical characterization and risk factors for underlying disease. Hepatology. 29:1999;664-669.
8. Ludwig J., Viggiano T.R., McGill D.B., Ott B.J. Non-alcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:1980;434-438.
9. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity an autopsy study with analysis of risk factors. Hepatology. 12:1990;1106-1110.
10. Fong D., Nehra V., Lindor K.D., Buchman A. Metabolic and nutritional considerations in non-alcoholic fatty liver. Hepatology. 32:2000;3-10.
11. Angulo P., Lindor K.D. Treatment of non-alcoholic fatty liver present and emerging therapies. Semin Liver Dis. 21:2001;81-88.
12. De Wind L.T., Payne J.H. Intestinal bypass surgery for morbid obesity long term results. JAMA. 236:1976;2298-2301.
13. Campbell J.M., Hunt T.K., Karam J.H., Forsham P.H. Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med. 137:1977;602-610.
14. Jepson R, Hetherington J. Glossary of epidemiological terms. In: Cochrane Reviewers' Handbook. London, United Kingdom: BMJ Publishing Group; 1996:1-29.
15. Park H.S., Kim M.W., Shin E.S. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci. 10:1995;414-421.
16. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 27:1997;103-107.
17. Rozental P., Biava C., Spencer H., Zimmerman H. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 12:1967;198-208.
18. Eriksson S., Eriksson K.F., Bondesson L. Non-alcoholic steatohepatitis in obesity a reversible condition. Acta Med Scand. 220:1986;83-88.
19. Ranlov I., Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 47:1990;208-214.
20. Andersen T., Gluud C., Franzmann M., Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 12:1991;224-229.
21. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects effect of drastic weight loss after gastroplasty. Int J Obes. 22:1998;222-226.
22. Knobler H., Schattner A., Zhornicki T., et al. Fatty liver an additional and treatable feature of the insulin resistance syndrome. QJM. 92:1999;73-79.
23. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 99:1990;1408-1413.
24. Keefe E.B., Adesman P., Stenzel P., Palmer R. Steatosis and cirrhosis in an obese diabetic resolution of fatty liver by fasting. Dig Dis Sci. 32:1987;441-445.
25. DeMeo M., Mobarhan S., Mikolaitis S., Kazi N. Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related disease. Nutrition Rev. 55:1997;297-302.
26. Sanyal A.J. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology. 123:2002;1705-1725.
27. Reisin E., Frohlich E.D., Messerli F.H., et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 98:1983;315-319.
28. Colditz G.A., Willett W.C., Rotnitzky A., Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122:1995;481-486.